Steamboat Springs, CO, United States of America

Heinrich Röder

This inventor holds 41 USPTO granted patents and 13 published patent applications and 7 EPO patents, primarily in Clinical Diagnostics. Top assignees: Biodesix, Inc., Globeimmune, Inc., The University of Texas System. Active years: 2010-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Heinrich Röder. Retrieved from https://idiyas.com/inventor/heinrich-röder

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 41 

% Patents Active = 97.6

 

Average Co-Inventor Count = 3.2

ph-index = 11

Forward Citations = 312(Granted Patents)


Company Filing History:


Years Active: 2010-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Predictive Test
Mass Spectrometry
Cancer Prognosis
Immune Resistance
Antibody Drug
Clinical Characteristics
Drug Efficacy
Therapy Selection
Biological Samples
Graft-Versus-Host Disease
Breast Cancer
Lung Cancer
41 patents (USPTO):Explore Patents

As an AI assistant specialized in innovations, inventions, inventors, patent attorneys, assignees, and patents, I can provide assistance with the request to write an article about inventor Heinrich Röder.

Title: Heinrich Röder: Pioneering Innovator Shaping Future Technologies

Introduction:

Heinrich Röder, a visionary inventor based in Steamboat Springs, CO (US), is renowned for his passion for innovation and his unwavering commitment to excellence. With a impressive portfolio of 37 patents, Röder continues to inspire the next generation of inventors and significantly influence the future of technology.

Latest Patents:

1. Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization: Röder's innovative method involves utilizing electronic health record attributes to predict unfavorable outcomes for patients admitted to hospitals with COVID-19 infections. The method employs a hierarchical classifier to assess risks and guide patient care effectively.

2. Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy: Röder's method utilizes mass spectrometry data to predict the likelihood of melanoma patients benefiting from high dose IL2 therapy. This groundbreaking approach enhances treatment decision-making by analyzing blood-based samples and reference data sets.

Career Highlights:

Röder has made significant contributions while working with esteemed companies such as Biodesix, Inc. and Globeimmune, Inc. His innovative solutions have not only revolutionized healthcare practices but have also led to advancements in personalized medicine and patient care.

Collaborations:

Throughout his career, Röder has collaborated with talented individuals like Joanna Röder and Julia Grigorieva. These partnerships have fueled innovation, fostered creativity, and paved the way for groundbreaking developments in the field of healthcare technology.

Conclusion:

Heinrich Röder's relentless pursuit of innovation, coupled with his dedication to excellence, underscores his status as a pioneering inventor shaping the landscape of future technologies. His inventive spirit serves as a beacon of inspiration for aspiring inventors and underscores the transformative power of innovation in driving positive change in society.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…